A forum for researchers, students and applicants in the field of cyclodextrin technology
Dissolving microneedles (DMNs) have been widely investigated for transdermal drug delivery, yet their clinical translation and commercialization remain limited, primarily
A recent review [1] used risperidone as a pharmacological model to examine the impact of solubility enhancement at the primary
Hydrogel-forming microneedle array patches (HFMAPs) are microneedles that create microconduits upon insertion and swelling in the skin, potentially allowing prolonged
